TQ Quiz | Game Changers: Therapeutic Innovations (Charleston 2025) by Events@optometricedu.com | Aug 6, 2025 | 2025 Charleston, TQ Courses | 0 comments "*" indicates required fields This field is hidden when viewing the formDate (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent 90 days past date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date Difference (Hidden)1. Which of the following medications is a preservative-free prostaglandin analog?* A - Travatan Z (travoprost ophthalmic solution) 0.004% B - Iyuzeh (latanoprost ophthalmic solution) 0.005% C - Lumigan (bimatoprost ophthalmic solution) 0.01% D - Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% 2. Rocklatan (netarsudil 0.02%/latanoprost 0.005%) dosage is correctly described as:* A - Every other day B - Once daily in the evening C - Twice daily D - Three times daily 3. Current treatment options for presbyopia include which of the following classes of medications?* A - Beta blockers B - Cholinergics C - Steroids D - Fluoroquinolones 4. What is the name of the FDA-approved dual-pathway inhibiting agent for the treatment of neovascular macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion?* A - Faricimab B - Tocilizumab C - Teprotumumab D - Bevacizumab 5. Possible adverse effects of intravitreal anti-VEGF injection include all but which of the following?* A - Elevated intraocular pressure B - Endophthalmitis C - Subconjunctival hemorrhage D - Myopia 6. Syfovre (pegcetacoplan) is FDA approved for the treatment of:* A - Neovascular AMD B - Geographic atrophy C - Intermediate stage non-exudative AMD D - Cystoid macular edema 7. Long-term use of topical ocular medications preserved with benzalkonium chloride (BAK) may cause which of the following?* A - Decreased goblet cell density B - Increased intraocular pressure C - Cystoid macular edema D - Hyperopic shift 8. Activation of the complement system ultimately leads to which cellular process?* A - Apoptosis B - Mitosis C - Respiration D - Transcription 9. FDA-approved biosimilars are available for which of the following anti-VEGF agents?* A - Ranibizumab B - Axitinib C - Brolucizumab D - Faricimab 10. Effects related to reversal of pharmacologic mydriasis with phentolamine 0.75% (Ryzumvi) were achieved approximately how quickly following instillation in clinical trials?* A - 10 minutes B - 60 minutes C - 2 hours D - 6 hours 11. Lotilaner 0.25% (Xdemvy) is on-label for the treatment of:* A - Signs and symptoms of dry eye disease B - Allergic conjunctivitis C - Reversal of mydriasis D - Demodex blepharitis 12. All of the following are anti-VEGF agents, EXCEPT:* A - Eylea B - Lucentis C - Iluvien D - Avastin 13. What is the difference between generic latanoprost 0.005% and Iyuzeh (latanoprost ophthalmic solution 0.005%)?* A - Mechanism of action B - Preservative C - Active ingredient D - Dosage 14. What is the primary mechanism of action of rho-kinase inhibitors?* A - Increased uveoscleral outflow B - Decreased aqueous production C - Increased trabecular outflow D - Increased episcleral venous pressure 15. Which topical ophthalmic IOP-lowering medication contains a nitric-oxide donating moiety?* A - Latanoprostene bunod 0.024% (Vyzulta) B - Netarsudil 0.02% (Rhopressa) C - Dorzolamide 2% D - Preservative-free latanoprost 0.005% (Iyuzeh) 16. The correct dosing of Vevye (cyclosporine ophthalmic solution) 0.1% is described as:* A - Once daily B - Twice daily C - Three times daily D - Four times daily 17. What is the mechanism of action of varenicline nasal spray in the treatment of signs and symptoms of dry eye disease?* A - Reduces tear film evaporation B - Inhibits cytokine release C - Acts as an antiparasitic agent D - Activates the trigeminal parasympathetic pathway 18. Why is lotilaner 0.25% (Xdemv) labeled for 6 weeks of treatment for Demodex blepharitis?* A - To match the lifecycle of Demodex mites B - To align with insurance coverage policies C - To reduce the need for preservative-free formulations D - To maximize adherence to treatment 19. How does the Valeda light delivery system function in dry AMD treatment?* A - Inhibits VEGF pathways B - Uses photobiomodulation to stimulate mitochondrial function C - Targets complement inhibition D - Acts as a rho kinase inhibitor 20. What is the mechanism of action for 100% perfluorohexyloctane (Miebo) in the treatment of the signs and symptoms of dry eye disease?* A - Increased tear production B - Stabilization of the tear film and reduces evaporation C - Inhibition of complement activation D - Reduction in intraocular pressure Personal InformationName* First Last Email* Phone*OE Tracker #License #Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional CodeCharleston 2025 - Identifying True Ocular Emergencies of the Posterior Pole*After 90 days, pricing will increase to $30. Price: Retake Discount Price: Promotional Discount Price: Credit Card* This field is hidden when viewing the formCourse Information (HIDDEN)This field is hidden when viewing the formCourse Name (HIDDEN)This field is hidden when viewing the formRetake Code (HIDDEN)This field is hidden when viewing the formQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/)This field is hidden when viewing the formCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
